FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2247107510> ?p ?o ?g. }

• W2247107510 abstract "Abstract Abstract 3673 Background: Impaired systemic immunity is an established risk factor for the development of B-cell lymphoma. However current understanding of the underlying mechanisms of cell-mediated immune evasion and how this varies during chemo-immunotherapy remains rudimentary. Studies have been hampered by retrospective analysis of heterogenous cohorts containing both new and relapsed patients, with a variety of indolent/aggressive histological subtypes, treated with different treatment regimens. Methods: We performed detailed analysis of circulating immune cell populations in 33 patients (mean age 53 years, range 31 – 69, F:M 11:22) with newly diagnosed high-risk diffuse large B-cell lymphoma (DLBCL) enrolled in a prospective multi-centre Australasian Leukaemia & Lymphoma Group trial. They received 3 cycles of CHOP-R-14, and then after a 4th cycle underwent an interim-PET/CT with centralized review performed at day 17–20 (to enable risk-stratification). Pegylated-GCSF was given on day 2 after each cycle. PET/CT metabolic response categorisation used the harmonisation criteria. 10/33 evaluable patients remained interim-PET/CT avid. Blood samples were taken pre-treatment and on day 21 post-cycle 4, and compared to 23 age/gender-matched healthy control subjects. Results were correlated with interim-PET/CT response status. Laboratory investigators were blinded to clinical results. Results: CD3+, CD8+ and CD4+ T-cells (p=00.21, p=0.005, p=0.0017) among patients with DLBCL were all reduced at pre-treatment compared to controls. After 4 cycles, CD4+ lymphocytes were reduced further (p=0.0003) whereas CD3+ and CD8+ counts remained unchanged. However, CD3+, CD8+ and CD4+ proliferative responses to CD28/CD3 stimulation were equivalent to healthy subjects at both time-points, indicating the absence of an intrinsic functional T-cell defect in response to stimulation. Nor were regulatory T-cells (CD4+CD25hiCD127−) or myeloid-derived suppressor cells (CD33+CD14−HLA-DR−) altered between time-points or as compared to healthy subjects. Circulating monocytes are key regulators of inflammation/ immunity. Absolute monocyte counts were strikingly elevated at pre-treatment compared to healthy subjects (p=0.007), and had a predominantly CD14+HLA-DR−/lo phenotype. Importantly, pre-treatment values for absolute monocytes (p=0.04), monocyte % (p=0.004), CD14+HLA-DR−/lo monocytes (p=0.03), mean fluorescent intensity of HLA-DR on CD14+ monocytes (p=0.025) and CD3+ T-cells (p=0.0374), were all associated with persistent interim-PET/CT avidity. However, all were independent of the international prognostic index (IPI) score, and IPI did not segregate with interim-PET/CT status. Post-cycle 4 monocyte % (p=0.048) and CD3+ T-cells (p= 0.029) were also related to interim-PET/CT avidity. The CD14+HLA-DR−/lo phenotype has been described as immunosuppressive (Lin, Blood 2011). Consistent with this, in-vitro depletion of monocytes from pre-treatment (p=0.03) and post-cycle 4 (p=0.04) samples enhanced CD4+ proliferation. By contrast, monocyte depletion from control samples did not influence CD4+ proliferation. Post-cycle 4 monocytes rose above pre-treatment levels (p=0.0301) as did fluorescent intensity of HLA-DR on CD14+ monocytes (p=0.0027). In line with the post-cycle 4 reduction of the CD14+HLA-DR−/lo ratio (p=0.0135), plasma arginase was reduced relative to pre-treatment (p=0.0035), suggesting that suppression was mediated in part through arginine metabolism. HLA-DR expression on monocytes at the interim time-point was up-regulated from pre-treatment (p=0.01), and accompanied by a relative increase in ex-vivo blood myeloid dendritic cells (BMDCs; p=0.044), suggesting the CD14+HLA-DR−/lo phenotype is associated with an impaired ability to differentiate into BMDCs in-vivo. Conclusion: Monocytes in DLBCL mediate immunosuppression of T-cells and both appear to be associated with interim-PET/CT avidity. Although the role of interim-PET/CT in DLBCL patients treated with chemo-immunotherapy is an area of considerable activity, the study of biological predictors of metabolic response has been relatively neglected. To the best of our knowledge, this is the first prospective study to find an association between cellular markers of inflammation/ immunity and interim-PET/CT avidity in a cohort of uniformly treated high-risk DLBCL patients. Disclosures: No relevant conflicts of interest to declare." @default.
• W2247107510 created "2016-06-24" @default.
• W2247107510 creator A5000810005 @default.
• W2247107510 creator A5008582950 @default.
• W2247107510 creator A5009444261 @default.
• W2247107510 creator A5027054405 @default.
• W2247107510 creator A5028575111 @default.
• W2247107510 creator A5031674725 @default.
• W2247107510 creator A5069441736 @default.
• W2247107510 creator A5078466953 @default.
• W2247107510 creator A5081326206 @default.
• W2247107510 creator A5081797509 @default.
• W2247107510 date "2011-11-18" @default.
• W2247107510 modified "2023-10-14" @default.
• W2247107510 title "Monocytes Are Associated with Impaired T-Cell Immunity and Residual Interim-PET/CT Avidity After 4 Cycles of CHOP-R In Patients with High-Risk DLBCL," @default.
• W2247107510 doi "https://doi.org/10.1182/blood.v118.21.3673.3673" @default.
• W2247107510 hasPublicationYear "2011" @default.
• W2247107510 type Work @default.
• W2247107510 sameAs 2247107510 @default.
• W2247107510 citedByCount "2" @default.
• W2247107510 countsByYear W22471075102013 @default.
• W2247107510 countsByYear W22471075102015 @default.
• W2247107510 crossrefType "journal-article" @default.
• W2247107510 hasAuthorship W2247107510A5000810005 @default.
• W2247107510 hasAuthorship W2247107510A5008582950 @default.
• W2247107510 hasAuthorship W2247107510A5009444261 @default.
• W2247107510 hasAuthorship W2247107510A5027054405 @default.
• W2247107510 hasAuthorship W2247107510A5028575111 @default.
• W2247107510 hasAuthorship W2247107510A5031674725 @default.
• W2247107510 hasAuthorship W2247107510A5069441736 @default.
• W2247107510 hasAuthorship W2247107510A5078466953 @default.
• W2247107510 hasAuthorship W2247107510A5081326206 @default.
• W2247107510 hasAuthorship W2247107510A5081797509 @default.
• W2247107510 hasConcept C126322002 @default.
• W2247107510 hasConcept C143998085 @default.
• W2247107510 hasConcept C2778559949 @default.
• W2247107510 hasConcept C2779338263 @default.
• W2247107510 hasConcept C535046627 @default.
• W2247107510 hasConcept C61943457 @default.
• W2247107510 hasConcept C71924100 @default.
• W2247107510 hasConcept C90924648 @default.
• W2247107510 hasConceptScore W2247107510C126322002 @default.
• W2247107510 hasConceptScore W2247107510C143998085 @default.
• W2247107510 hasConceptScore W2247107510C2778559949 @default.
• W2247107510 hasConceptScore W2247107510C2779338263 @default.
• W2247107510 hasConceptScore W2247107510C535046627 @default.
• W2247107510 hasConceptScore W2247107510C61943457 @default.
• W2247107510 hasConceptScore W2247107510C71924100 @default.
• W2247107510 hasConceptScore W2247107510C90924648 @default.
• W2247107510 hasLocation W22471075101 @default.
• W2247107510 hasOpenAccess W2247107510 @default.
• W2247107510 hasPrimaryLocation W22471075101 @default.
• W2247107510 hasRelatedWork W1497769182 @default.
• W2247107510 hasRelatedWork W1832098911 @default.
• W2247107510 hasRelatedWork W1982989360 @default.
• W2247107510 hasRelatedWork W1987280240 @default.
• W2247107510 hasRelatedWork W2188177124 @default.
• W2247107510 hasRelatedWork W2348868409 @default.
• W2247107510 hasRelatedWork W2352169854 @default.
• W2247107510 hasRelatedWork W2384380598 @default.
• W2247107510 hasRelatedWork W2402738982 @default.
• W2247107510 hasRelatedWork W2463722750 @default.
• W2247107510 hasRelatedWork W2554268079 @default.
• W2247107510 hasRelatedWork W2562543800 @default.
• W2247107510 hasRelatedWork W2563112719 @default.
• W2247107510 hasRelatedWork W2587045623 @default.
• W2247107510 hasRelatedWork W2995516825 @default.
• W2247107510 hasRelatedWork W2999051750 @default.
• W2247107510 hasRelatedWork W3030101686 @default.
• W2247107510 hasRelatedWork W3030963131 @default.
• W2247107510 hasRelatedWork W3031829407 @default.
• W2247107510 hasRelatedWork W3164010709 @default.
• W2247107510 isParatext "false" @default.
• W2247107510 isRetracted "false" @default.
• W2247107510 magId "2247107510" @default.
• W2247107510 workType "article" @default.